Chronic Rhinosinusitis with Nasal Polyps Market Shows Strong Upward Momentum During the Forecast Period (2026-2036) as Demand for Advanced Therapies Rises | DelveInsight
The chronic rhinosinusitis with nasal polyps market growth is being driven by rising disease prevalence, greater awareness, and improved diagnostic rates. Advancements in biologic therapies are expanding treatment options and significantly boosting market demand. Additionally, the launch of emerging therapies such as Depemokimab (GlaxoSmithKline), Verekitug (UPB-101) (Upstream Bio), Lunsekimig (Sanofi), LY3650150 (Eli Lilly), and others will further propel the market growth.
LAS VEGAS, March 5, 2026 /PRNewswire/ -- Recently published Chronic Rhinosinusitis with Nasal Polyps Market Insights report includes a comprehensive understanding of current treatment practices, chronic rhinosinusitis with nasal polyps emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Chronic Rhinosinusitis with Nasal Polyps Market Summary
Discover what is the forecast for the global CRSwNP market @ https://www.delveinsight.com/sample-request/chronic-rhinosinusitis-with-nasal-polyps-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr
Key Factors Driving the Growth of the Chronic Rhinosinusitis with Nasal Polyps Market
Ramandeep Singh, Senior Consultant, Forecasting and Analytics at DelveInsight, said that the treatment strategies are shifting beyond conventional intranasal corticosteroids, systemic steroids, and surgery toward targeted biologic therapies, enabling more personalized and sustained disease control for patients.
Chronic Rhinosinusitis with Nasal Polyps Market Analysis
Chronic Rhinosinusitis with Nasal Polyps Competitive Landscape
CRSwNP pipeline possesses some drugs in late stage developments to be approved in the near future. Expected launch of emerging therapies, such as Depemokimab (GlaxoSmithKline), Verekitug (UPB-101) (Upstream Bio), Lunsekimig (Sanofi), LY3650150 (Eli Lilly), and others, are expected to further create a positive impact on the market.
Upstream Bio's Verekitug is an engineered, fully human IgG1 monoclonal antibody that targets the TSLP receptor, blocking TSLP-driven pro-inflammatory signaling. In preclinical testing, it showed strong receptor occupancy and robust inhibition of TSLP pathways. Verekitug also reduced cytokine release from CD4+ T cells and ILC2s and completely prevented allergic skin responses in a non-human primate model, indicating potential effectiveness across multiple inflammatory conditions.
GSK is developing depemokimab as a treatment for CRSwNP. This humanized monoclonal antibody against interleukin-5 (IL-5) is designed to bind IL-5 with high affinity and provide long-lasting suppression of IL-5–dependent activity, supporting extended control of eosinophil-driven inflammation.
The anticipated launch of these emerging therapies are poised to transform the CRSwNP market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the CRSwNP market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about emerging drugs for chronic sinusitis with nasal polyps @ Chronic Rhinosinusitis with Nasal Polyps Drugs
Recent Developments in the Chronic Rhinosinusitis with Nasal Polyps Market
What is Chronic Rhinosinusitis with Nasal Polyps?
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a long-lasting inflammatory condition of the nose and sinuses in which soft, painless, noncancerous growths, called nasal polyps, develop inside the nasal passages or sinus cavities. These polyps form when the lining of the nose becomes persistently swollen and irritated, often due to immune system dysfunction. People with CRSwNP commonly experience symptoms such as nasal blockage, reduced or lost sense of smell, facial pressure, congestion, and recurring sinus infections. Because the inflammation is ongoing and the polyps tend to recur even after treatment, CRSwNP is considered a chronic condition that often requires long-term medical management.
Chronic Rhinosinusitis with Nasal Polyps Epidemiology Segmentation
The CRSwNP epidemiology section provides insights into the historical and current CRSwNP patient pool and forecasted trends for the leading markets. The US had the highest diagnosed prevalent cases of CRSwNP in the 7MM, with around 2 million cases in 2025. The gender distribution of the disease suggests a male predominance in the US, with 55% of the diagnosed prevalent cases of CRSwNP being males.
The CRSwNP treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:
Chronic Rhinosinusitis with Nasal Polyps Market Report Metrics
Details
Study Period
2022–2036
Coverage
7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Chronic Rhinosinusitis with Nasal Polyps Epidemiology Segmentation
Prevalent Cases of CRS, Diagnosed Prevalent Cases of CRS, Diagnosed Prevalent Cases of CRSwNP, Gender-specific Diagnosed Prevalent Cases of CRSwNP, and Total Treated Cases of CRSwNP
Key Chronic Rhinosinusitis with Nasal Polyps Companies
Upstream Bio, GlaxoSmithKline, Sanofi, Eli Lilly, AstraZeneca, Amgen, Regeneron Pharmaceuticals, and others
Key Chronic Rhinosinusitis with Nasal Polyps Therapies
Verekitug (UPB-101), Depemokimab (GSK3511294), Lunsekimig, LY3650150, NUCALA, TEZSPIRE, DUPIXENT, and others
Scope of the Chronic Rhinosinusitis with Nasal Polyps Market Report
Download the report to understand CRSwNP market CAGR projections @ Chronic Rhinosinusitis with Nasal Polyps Market Analysis
Table of Contents
1
Chronic Rhinosinusitis with Nasal Polyps Market Key Insights
2
Chronic Rhinosinusitis with Nasal Polyps Market Report Introduction
3
Nasal Polyps Market Overview at a Glance
3.1.
Market Share (%) Distribution of CRSwNP by Therapies in 2025
3.2.
Market Share (%) Distribution of CRSwNP by Therapies in 2036
4
Epidemiology and Market Forecast Methodology
5
Executive Summary
6
Key Events
7
Disease Background and Overview
7.1.
Introduction
7.2.
Signs and Symptoms
7.3.
Etiology
7.4.
Causes
7.5.
Pathogenesis
7.6.
Diagnostic Approach
7.7.
Treatment and Management
8
Epidemiology and Patient Population
8.1.
Key Findings
8.2.
Methodology of Epidemiology
8.3.
Assumptions and Rationale: the 7MM
8.3.1.
The US
8.3.2.
EU4 and the UK
8.3.3.
Japan
8.4.
Total Diagnosed Prevalent Cases of CRSwNP in the 7MM
8.5.
The United States
8.5.1.
Prevalent Cases of CRS in the US
8.5.2.
Diagnosed Prevalent Cases of CRS in the US
8.5.3.
Diagnosed Prevalent Cases of CRSwNP in the US
8.5.4.
Gender-specific Diagnosed Prevalent Cases of CRSwNP in the US
8.5.5.
Total Treated Cases of CRSwNP in the US
8.6.
EU4 and the UK
8.7.
Japan
9
CRSwNP Patient Journey
10
Marketed CRSwNP Therapies
10.1.
Key Cross Competition
10.2.
NUCALA (mepolizumab): GlaxoSmithKline
10.2.1.
Product Description
10.2.2.
Regulatory Milestones
10.2.3.
Other Developmental Activities
10.2.4.
Clinical Trials Information
10.2.5.
Safety and Efficacy
10.2.6.
Analyst Views
10.3.
TEZSPIRE (tezepelumab): AstraZeneca/Amgen
10.4.
DUPIXENT (dupilumab): Sanofi/Regeneron Pharmaceuticals
List to be continued in the final report
11
Emerging CRSwNP Drugs
11.1.
Key Cross Competition
11.2.
Verekitug (UPB-101): Upstream Bio
11.2.1.
Product Description
11.2.2.
Other Developmental Activities
11.2.3.
Clinical Development
11.2.4.
Clinical Trials Information
11.2.5.
Safety and Efficacy
11.2.6.
Analyst Views
11.3.
Depemokimab (GSK3511294): GlaxoSmithKline
List to be continued in the final report
12
CRSwNP: Market Analysis
12.1.
Key Findings
12.2.
Key CRSwNP Market Forecast Assumptions
12.3.
CRSwNP Market Outlook
12.4.
Attribute Analysis
12.5
Total Market Size of CRSwNP in the 7MM
12.6
Market Size of CRSwNP by Therapies in the 7MM
12.7
Market Size of CRSwNP in the US
12.7.1.
Total Market Size of CRSwNP in the US
12.7.2.
Market Size of CRSwNP by Therapies in the US
12.8
Market Size of CRSwNP in EU4 and the UK
12.9
Market Size of CRSwNP in Japan
13
KOL Views on CRSwNP
13.1.
The United States
13.2.
The EU4 and the UK
13.3.
Japan
14
CRSwNP Market SWOT Analysis
15
CRSwNP Market Unmet Needs
16
Reimbursement and Market Access
16.1
The US
16.2
In EU4 and the UK
16.3
Japan
17.
Bibliography
18
Abbreviations and Acronyms
19
CRSwNP Market Report Methodology
Related Reports
Chronic Rhinosinusitis with Nasal Polyps Clinical Trial Analysis
Chronic Rhinosinusitis with Nasal Polyps Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key CRSwNP companies, including Keymed Biosciences Co., Ltd., GlaxoSmithKline, Genrix (Shanghai) Biopharmaceutical Co., Ltd., Guangdong Hengrui Pharmaceutical Co., Ltd, and others.
Chronic Rhinosinusitis without Nasal Polyps Market
Chronic Rhinosinusitis without Nasal Polyps Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CRSsNP companies including Optinose US Inc., Lyra Therapeutics, Insmed, Inc., Sanofi, Regeneron Pharmaceuticals, and others.
Chronic Rhinosinusitis Market
Chronic Rhinosinusitis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key chronic rhinosinusitis companies including Connect Biopharma, Lyra Therapeutics, Sanotize Research and Development Corp., Regeneron Pharmaceuticals, AstraZeneca, Kyowa Kirin Co., Ltd., Keymed Biosciences Co.Ltd, Pfizer, GlycoMira Therapeutics, and others.
Nasal Polyps Market
Nasal Polyps Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key nasal polyps companies including Sanofi, Regeneron, GSK, Optinose, AstraZeneca, Novartis, Intersect ENT Inc., Teva Pharmaceutical Industries, Merck & Co., Cipla Ltd., Dr. Reddy's Laboratories, Genentech (Roche), Sun Pharmaceutical Industries, Lyra Therapeutics, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
[email protected]
+14699457679
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
SOURCE DelveInsight Business Research, LLP